Investor Presentaiton

Oncology Opdivo Opdualag TIGIT Bispecific DGK Inhibitor AR LDD MSS CRC: Combination benefit where PD-1 alone has not shown activity Patient with recurrent, metastatic MSS rectal adenocarcinoma after 3 lines of treatment in the metastatic setting DOD Baseline 3 months into treatment 9 months into treatment Partial Response (-38% decrease) in target lesions for 11+ months RELATIVITY-123 Phase 3 ongoing: Opdualag vs regorafenib or TAS-102 in later lines of metastatic colorectal cancer Data expected in 2025 Ill Bristol Myers Squibb™ Images courtesy of Dr. Eric Christenson and Dr. Dung Le, Johns Hopkins University Not for Product Promotional Use 100

View entire presentation